Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future - Wikidata - awgldk - TriplyDB

Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future

Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future

http://www.wikidata.org/entity/Q26853631

about

Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B Practical aspects of extended half-life products for the treatment of haemophilia

P2860

Q37623821-0EE743CE-C937-4973-B627-772615414F37 Q58706077-803B4CE1-E6F5-4CD7-9F24-C188CD9B8230 Q58761664-D383E043-2235-4557-A6A3-162B745488F9

P2860

Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future

http://www.wikidata.org/entity/Q26853631

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Achieving and maintaining an o ...... st, the present and the future

@ast

Achieving and maintaining an o ...... st, the present and the future

@en

Achieving and maintaining an o ...... st, the present and the future

@nl

type

label

Achieving and maintaining an o ...... st, the present and the future

@ast

Achieving and maintaining an o ...... st, the present and the future

@en

Achieving and maintaining an o ...... st, the present and the future

@nl

prefLabel

Achieving and maintaining an o ...... st, the present and the future

@ast

Achieving and maintaining an o ...... st, the present and the future

@en

Achieving and maintaining an o ...... st, the present and the future

@nl

P1433

Q26853631-01E52C3A-63EC-474A-9911-C839F6EBA23C

P1476

Q26853631-8E964219-B60B-406B-9457-3B7CF9EDDBC9

P2093

Q26853631-0BD7EE99-E9BA-48AE-9A57-4A59138FCD5C

Q26853631-29EE22C5-6E98-4BAE-AEB3-4E64B60F7FB4

Q26853631-67CF0707-99AC-4E13-B9D3-A97CE9A8FCEF

Q26853631-9C0DCAD4-DF89-4C41-8AE9-1B3E402AC2C1

Q26853631-EBAC8EA7-0AA7-4B66-BFC1-3C47C0DE64FF

P2860

Q26853631-14C8232F-CD22-4958-B808-F43E6F1AA84A

Q26853631-15A40B7B-0DB5-4D08-B89E-749DC434A64A

Q26853631-16D8A769-D65B-4329-97DD-E7365435EFFD

Q26853631-20D349D8-975E-4283-AD75-BF3D967E3A5B

Q26853631-23B70E2D-B348-4352-B481-1D861ECAFE22

Q26853631-2F40BC5A-1E8D-40AA-A3EE-4144866C370C

Q26853631-32306766-CFC4-4D6D-A0E4-AEBF16245964

Q26853631-52F88E8E-F2C2-4804-801F-E260ED388C87

Q26853631-61660F29-8D39-40ED-A1E2-3243935349CC

Q26853631-646E7CAD-AB63-4335-8C1F-E982E5CDEE47

P304

Q26853631-7B5259FF-05B8-44A0-9C04-6A3D2B00EF29

P31

Q26853631-B08F8B9F-C3B2-428E-990C-E5CCDDBBF391

P356

Q26853631-EBC4545B-CBB4-41CD-8DFE-3536C76EDDEA

P407

Q26853631-7531F371-69B5-482D-96D4-79DEE1AD53D8

P433

Q26853631-6F90FD2F-7DA3-42C5-998D-9E0E5A01AC03

P478

Q26853631-B619CA92-D70A-421E-A1EA-3885F9A4488C

P50

Q26853631-93503ABD-9E45-439A-885D-E86249B56629

Q26853631-99D5A954-4C03-4F73-AE5D-68065E19FC21

P577

Q26853631-1E3BB44E-585E-472B-9D55-9664EB6838E8

P5875

Q26853631-194FC5F4-C1FA-4BFD-9C69-D32D3D2AB434

P698

Q26853631-81105639-BF1C-4F74-AD0E-939982D7D1AD

P921

Q26853631-BD8E515C-5D3F-4669-9FF8-274C28EF7931

P932

Q26853631-D9F4F4E1-33BD-4DBD-9216-CAE27A01E043

P356

P1433

Blood transfusion = Trasfusione del sangue

P1476

Achieving and maintaining an o ...... st, the present and the future

@en

P2093

Gary Benson

http://www.w3.org/2001/XMLSchema#string

Günter Auerswald

http://www.w3.org/2001/XMLSchema#string

Massimo Morfini

http://www.w3.org/2001/XMLSchema#string

Silva Zupančić Salek

http://www.w3.org/2001/XMLSchema#string

Thierry Lambert

http://www.w3.org/2001/XMLSchema#string

P2860

Future of coagulation factor replacement therapy

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels.

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

Blood-induced joint disease: the pathophysiology of hemophilic arthropathy.

A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.

P304

314-319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2450/2014.0298-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Víctor Jiménez-Yuste

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264240312

http://www.w3.org/2001/XMLSchema#string

P698

25074524

http://www.w3.org/2001/XMLSchema#string

P921

P932

4111811

http://www.w3.org/2001/XMLSchema#string